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ABSTRACT
Benzodiazepines are a psychoactive drug class used to treat anxiety, insomnia, and more.
While they have a relatively uninteresting prescription pattern when viewed in isolation, their coprescription rates with opioids are rising. This pattern is associated with increased risk of abuse
and mortality in patients and is against public health guidance. To date, detailing payments made
from pharmaceutical manufacturers to physicians have not been investigated as a potential driver
of benzodiazepine prescription. This study uses the Open Payments database to offer a descriptive
analysis of detailing payments made to psychiatrists between 2014 and 2019, a new contribution
to pharmaceutical marketing literature. This study argues that detailing payments are unlikely to
be drivers of trends in benzodiazepine prescription and benzodiazepine-opioid co-prescription,
though further investigation into within-physician effects and different specialties should be
pursued. Policymakers, public health officials, and researchers in the field may be interested in
the findings.
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INTRODUCTION
Benzodiazepine prescriptions continue to increase in the United States, as do rates of
benzodiazepine-opioid co-prescription. This trend persists despite regulators’ and public health
officials’ concern about their misuse and their explicit guidance against benzodiazepine-opioid coprescription. It is likely that a several factors are driving these trends in benzodiazepine
prescriptions, among which are variables that routinely explain prescribing behavior across all
drug classes. One such variable is pharmaceutical marketing, specifically the use of detailing
payments while promoting a drug. “Detailing payments” refers to a marketing technique in which
representatives of a pharmaceutical company provide “gifts, information, samples, trips, honoraria
and other inducements… to physicians in order to encourage them to prescribe their drugs” (King
and Bearman 2017).
Research has demonstrated that pharmaceutical industry detailing payments to physicians
are positively correlated with increases in physician prescribing in the United States (Carey et al.
2020). Furthermore, a study in France found that doctors who received as little as a €10 gift
associated with benzodiazepine marketing had statistically significant higher levels of
benzodiazepine reimbursements in comparison to those who didn’t receive a gift (Lagnaoui et al.
2004). To date, no research has specifically investigated whether detailing payments could
similarly affect benzodiazepine prescribing behavior in the United States.
This project aimed to evaluate whether detailing payments related to benzodiazepines are
likely to explain prescribing behavior for benzodiazepines.

Detailing payments related to

benzodiazepines are defined as those which are attributable to a benzodiazepine or a selective
serotonin reuptake inhibitor, a common benzodiazepine substitute. Previous research suggests that
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payments for benzodiazepines will increase prescribing behavior and payments for substitutes will
decrease prescribing behavior.
The first audience that will be benefit from these findings are public health officials. A
more comprehensive understanding of the drivers behind the trend in benzodiazepine-related
overdoses will better inform the solutions developed to combat them. Similarly, policymakers
concerned about benzodiazepine-related overdoses stand to gain something from this research.
This project’s findings may help justify existing or new legislation controlling detailing payments
in accordance with public health concerns.

Pharmaceutical marketing executives may be

interested in this research, as well as researchers whose work centers on or is implicated by the
effect of detailing payments on prescribing behavior.
LITERATURE REVIEW
Why benzodiazepines?
Benzodiazepines are a psychoactive drug class commonly used as treatment for anxiety,
though they are also approved as treatment for insomnia, seizures, alcohol withdrawal, and other
afflictions. The first benzodiazepine, Librium, was discovered in 1955 and made commercially
available in 1960. Several other brand name benzodiazepines followed, including Valium, Xanax,
Klonopin, and more. Seventeen years after the introduction of Librium, benzodiazepines became
the most prescribed drug class in the world. By and large, benzodiazepines’ popularity owed itself
to the drugs’ broad set of approved indications and relative safety—that is, when they are
prescribed correctly. (Balon et al. 2020)
Benzodiazepines generally work best when prescribed over the course of a few weeks.
Long-term benzodiazepine use is associated with a various adverse health effects ranging from
physical dependence (Lader, Tylee, and Donoghue 2009) to increased risk of dementia
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(Penninkilampi and Eslick 2018). Benzodiazepines also work best when taken without other
depressants. When taken in combination with alcohol or other depressants, benzodiazepines can
cause severe and potentially fatal respiratory depression (Fraser 1998). This risk is especially
prominent in cases of benzodiazepine-opioid co-prescription.
From 1999 to 2019, nearly half a million Americans have overdosed and died using either
an illicit or prescription opioid (“Understanding the Epidemic” 2021). Opioid overdose deaths per
capita continue to rise year-on-year, as do the desires of all Americans to see this crisis resolved.
Benzodiazepine prescriptions and abuse are also on the rise, though these trends are much lower
profile than those concerning opioids (Agarwal and Landon 2019). Benzodiazepines generally
have a reputation as safe, effective treatments, and have consequently escaped mainstream scrutiny.
Increasingly, however, researchers are investigating the ways in which benzodiazepine
prescriptions interplay with opioid overdose deaths within the United States.
Research has demonstrated that the mortality risk associated with benzodiazepine-opioid
co-prescription is higher than that of prescriptions for either of the drugs on their own (Xu et al.
2020). It is currently against public health guidance for physicians to prescribe benzodiazepines to
an opioid user and vice versa. Despite this, the prescription of both drugs individually and in
combination are on the rise (Rhee 2019).
Though this growth is higher within the population of patients 65 years of age or older, it
is also observed across the total population (Brett et al. 2018). From 2003 to 2015, the rate at which
physician visits noted a benzodiazepine or opioid quadrupled, growing from 0.5% to 2%. The coprescribing rate of benzodiazepines with opioids and other central nervous system depressants
nearly tripled across the same period, growing from 1.0% to 2.9%. All in all, it is estimated that
benzodiazepines were co-prescribed in 19.2% of visits in which there was also an opioid, and
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opioids were co-prescribed in 26.4% of visits in which there was also a benzodiazepine in 2015.
Though it is unclear whether these trends generalize globally, benzodiazepine, opioid, and
benzodiazepine-opioid prescriptions are on the rise within the United States. (Agrawal et al. 2019)
Unfortunately, this increase in prescription rates is associated with an increase in mortality
rates. From 1999 to 2016, benzodiazepine-related mortality increased from 0.6 deaths per 100,000
people to 4.4 deaths per 100,000 people (Agrawal et al. 2019). Given the way the drugs interact
and the trends in prescription data, the consensus amongst the literature is that the increase in
benzodiazepine-opioid co-prescription is likely driving the increase in benzodiazepine-related
mortality.
Why detailing payments?
If co-prescribing these two drugs is against public health guidance and worsens mortality,
then why are rates of co-prescription rising? It is likely that no one thing explains this trend, and
researchers have only just begun to explore potential factors. Patients with anxiety disorders have
benzodiazepine prescriptions at double the rate patients without anxiety disorders do, and patients
with a mood disorder have benzodiazepine prescriptions at quadruple the rate patients without
mood disorders do (Lagnaoui et al. 2004). Polypharmacy status and chronic care visits are also
associated with higher rates of co-prescription, as is being younger and female (Rhee 2019).
All these analyses have used patient attributes to explain prescribing behavior. It is wellestablished, however, that there are variables completely removed from patients that also explain
physicians’ prescribing behavior. One such variable is the marketing of prescription drugs.
Broadly speaking, the marketing of a drug is positively associated with its prescription.
Research has demonstrated the effectiveness of several marketing practices as a means of
influencing prescribing behavior, including direct-to-consumer advertising, drug coupons, and
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detailing payments (Carey, Lieber, and Miller 2020). In the pharmaceutical industry, detailing
payments are those payments made from a manufacturer to a physician during one-on-one sales
interactions. These payments include consulting fees, gifts, entertainment, meals, speaking fees,
charitable contributions and more. Estimates widely vary as to how much the pharmaceutical
industry spends on detailing per year, as studies vary in how broadly they define the marketing
technique (e.g., some studies include the value of free samples in their calculations of detailing
payments whereas others do not). It is generally agreed, however, that the value of yearly detailing
payments within the United States routinely exceeds tens of billions of dollars (King et al. 2017).
The pharmaceutical industry spends so much on detailing payments because of their ability
to consistently increase the prescription of drugs. Detailing has been called the most effective
promotional marketing instrument available to pharmaceutical companies, as even small payments
have a statistically significant effect on prescribing behavior (Iyer, Derman, and Sanhu 2016). All
in all, one study estimates the return-on-investment for detailing payments to be 10-to-1 for new
branded drugs and 2-to-1 for all drugs (Schwartz and Woloshin 2019).
There is a clear conflict of interest for physicians accepting these payments (Appelbaum
and Gold 2010). The prescription of drugs according to financial incentives as opposed to a
medical appropriateness presents issues for patients. No patient would want to be prescribed a drug
that (s)he does not need, nor would he want a drug that is suboptimal for his needs. Less obvious
though is the economic burden placed on these patients because of detailing. Studies have shown
that physicians who receive detailing payments routinely incur higher medical costs than those
who do not. One paper estimates that “a 10% or $25 increase in annual industry payments would
be associated with approximately $1,100 higher medical costs and $100 higher drug costs” (Meija,
Meija, and Pestilli 2019).
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Because of these health and financial concerns, legislation has been passed to implement
oversight on detailing payments to physicians. Arguably most significant legislation was the
Physician Payments Sunshine Act of 2010 (PPSA), passed as part of the Affordable Care Act. The
PPSA requires drug manufacturers and medical device companies marketing products in the
United States to report all detailing payments greater than $10 in value (Perlis and Perlis 2019).
Along with the value of the payment, the manufacturers need to report to whom they made the
payment, what the payment consisted of (e.g., a meal, speaking fees, etc.), when the payment was
made, for what product the payment concerned, and more. All this data is publicly available
through the Open Payments database.
Much work has been done on detailing payments since the publication of this database in
2013. Within the literature, there is a particular emphasis on opioids and prescription stimulants,
two commonly abused drug classes that currently include high-profile, brand-name products
(Hadland et al. 2017, Hadland et al. 2020). No study has used the database to investigate what
benzodiazepine detailing payments look like in the United States, let alone their development over
time. This study aimed to accomplish both and use those findings to judge whether detailing
payments could drive prescribing behavior.
METHODS
Data Source
In response to demand for greater oversight of detailing payments, the Obama
administration passed the Physician Payments Sunshine Act of 2010 and in doing so created the
Open Payments national disclosure program. From 2013 onwards, all detailing payments made
from all drug manufacturers to all physicians (so long as they are not residents or employed by the
manufacturer) have been recorded and published in a publicly available database. The data in Open
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Payments is both granular and far-reaching; all detailing payments of at least $10 in value are
included in the database, accompanied with information about the physician that accepted the
payment, the product the payment concerned, and in what form the payment came (e.g., a meal,
speaking fees, etc.). Because of its scope and detail, many studies on pharmaceutical marketing
use the Open Payments program as a detailing payments data source. This project followed suit
out of a desire to be consistent with the literature and to use the most comprehensive data available.
Analysis
This project employed the use of R statistical software to analyze the Open Payments data
between 2014 and 2019. These years were selected for two reasons. The earlier bound was
selected because pharmaceutical marketing literature already contains several analyses of Open
Payments data through 2013. This is likely a reflection of the heightened interest in the data during
its first years of being available to researchers. The later bound was selected to prevent COVID19-related impacts from skewing the results of the analysis. These impacts are not yet well-defined
in the literature, though they are likely to have been severe. A surface-level look at payments in
2019 and payments in 2020 show that detailing payments nearly halved in frequency. Further
investigation into the effect of COVID-19 on detailing payments to physicians is necessary.
The intended design of this project was a difference-in-difference design to discern the
causal effect of detailing payments on benzodiazepine prescriptions and benzodiazepine-opioid
co-prescription. After some exploratory data analysis, this design had to be scrapped because
detailing payments for benzodiazepines and their substitutes are nearly non-existent. Figure 1
records the number of physicians receiving at least one detailing payment for an SSRI or
benzodiazepine product listed as a commonly prescribed medicine for anxiety disorders by the
Anxiety Disorders Association of America for a given year. No physician received a detailing
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payment for any benzodiazepine product between 2014-2019, and no more than 10 received a
detailing payment for any SSRI product across the same period.
Before asking to what extent payments can explain the prescribing of benzodiazepines and
other psychoactive drugs, current trends in payments for these drugs must be better understood.
This project consequently turned its focus to descriptive analysis of detailing payments between
2014 and 2019, something not yet present in pharmaceutical marketing literature.
Analyzing all detailing payments was too broad of an effort to trace back in any meaningful
way to benzodiazepine prescription. After considering a few ideas to narrow down the dataset,
this project focused in on detailing payments made to psychiatrists. Psychiatrists were selected as
a sub-population for a few reasons. Across all physicians, psychiatrists account for the highest
share of benzodiazepine prescriptions in the United States outside of primary care providers (Santo
et. al 2020). Psychiatrists also are particularly prone to detailing efforts because of their specialty:
The flexible boundaries of many psychiatric diagnostic categories, in the absence of
definitive diagnostic tests, may encourage expansive definitions of affected populations
and create opportunities for industry to promote treatments for people who would not
previously have been seen as having a disorder… Relative exclusion of psychiatrists from
providing psychotherapy—a consequence of many managed care approaches—may also
continue to push the field toward a psychopharmacologic orientation. Finally, the existence
of similar compounds with roughly equivalent levels of efficacy and similar side-effect
profiles (e.g., the selective serotonin reuptake inhibitors) creates an incentive for
companies to undertake extensive efforts to distinguish their products from essentially
equivalent compounds. (Appelbaum and Gold 2010)
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That said, there is a large trade-off here in terms of scope. The results of the following
descriptive analysis should be limited in their extrapolation, and further investigation into detailing
payments made to all physicians should be pursued.
The descriptive analysis was done along three dimensions: incidence, magnitude, and
concentration. The incidence of detailing payments refers to how frequently they occurred.
Quantifying the magnitude of detailing payments means to quantify how much pharmaceutical
companies paid out to psychiatrists both on an individual and aggregated basis. Lastly, analyzing
the concentration of detailing payments refers to analyzing the extent to which payments were
concentrated in value to a smaller sub-population of psychiatrists.
RESULTS
Incidence
The number of psychiatrists receiving at least one payment over the course of the year
steadily declined between 2014 and 2019. The number of psychiatrists receiving at least one
payment peaked in 2014 at 23,346. By 2019, the number declined to 19,642. See Figure 2 for
more details.
Relative to other specialties, payments to psychiatrists became slightly less frequent over
time. In 2014, 3.73% of payments could be attributed to psychiatrists. By 2019, the number
declined to 3.12%. See Figure 3 for more details.
Magnitude
On an aggregated basis, detailing payments to psychiatrists increased between 2014 and
2019.

The total of industry payments to psychiatrists rose from $50,397,807 in 2014 to

$58,652,395 in 2019, an increase of roughly 16%. Payments in 2019 declined slightly from a peak
of $59,011,080 in 2018. See Figure 4 for more details.
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Relative to other specialties, the trend is less clear. The proportion of overall payment
value attributable to payments made to psychiatrists increased between 2014 and 2019, though it
took a sharp downturn in 2019. Regardless, this proportion has remained relatively small over
time, never dropping below 2.38% or rising above 2.65%. See Figure 5 for more details.
Detailing payments to psychiatrists also rose on an individual basis. Payments were
summed aggregated by physician over the course of the year to account for wide discrepancies in
payment value by type. Both the mean and median cumulative payment value per physician
increased over time. The average cumulative payment value increased from $2,159 in 2014 to
$3,014 in 2019, a roughly 39.6% increase. The median increased from $156 to $168 over the same
period. The discrepancy between the mean and median values are a result of the rightward skew
of the distribution of payment values. See Figures 6 and 7 for more details.
Concentration
The mentioned rightward skew of the distribution of payment values is also apparent when
analyzing the physicians who received the most detailing payments over the course of a year. Both
the 90th and 99th percentile of cumulative payments per psychiatrist increased significantly between
2014 and 2019. In 2014, the 90th and 99th percentile of cumulative payments per psychiatrist were
$1,402 and $42,627 respectively. In 2019, they were $1,563 and $70,972. This represents an
increase of roughly 11% and 43% for the 90th and 99th percentiles respectively. See Figures 8 and
9 for more details.
Previous studies of detailing payments analyze the proportion of payments over $10,000
in value relative to all payments as a way of measuring concentration. This can be done by quantity
of payments and value of payments. In 2014, just 3.08% of psychiatrists received payments
throughout the year totaling $10,000 or more in value. Yet, the payments these psychiatrists
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received made up 78.9% of the value of all detailing payments made to psychiatrists for that year.
In 2019, these figures were 3.79% and 84.7%. While the growth of the number of physicians
receiving $10,000 or more in payments outpaces the growth of the value attributable to these
physicians’ payments, the overall landscape remains highly concentrated. See Figures 10 and 11
for more details.
DISCUSSION
This project used detailing payments made to psychiatrists can be used as a proxy to study
marketing trends behind psychoactive drugs. These payments appear to be 1) decreasing in
frequency, 2) increasing in magnitude, and 3) consistently highly concentrated in value among a
few physicians. If detailing payments were to have a significant within-physician effects on
prescribing behavior, we might expect to see that influence play out in a small number of
physicians. Alternatively, detailing payments might exert an effect on prescribing behavior
through targeted influencers within certain physician communities.
That said, detailing payments are unlikely to be drivers of benzodiazepine prescribing
behavior. Between 2014 and 2019, no detailing payments were made to any physician in the
United States. Detailing payments to benzodiazepines’ main substitute, SSRIs, were few and far
between and concentrated to no more than 10 physicians in a year. For this same reason, it is also
unlikely that detailing payments are drivers of benzodiazepine and opioid co-prescription. More
likely drivers of benzodiazepine-opioid co-prescription are patient attributes, such as
polypharmacy status and chronic care visits. Further investigation with a more rigorous design
and representative population should be pursued to confirm this.
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APPENDIX
Figure 1
Drug Class
Benzodiazepines

SSRIs

Drug Name
Atvian
Dalmane
Klonopin
Halcion
Librium
Restoril
Serax
Tranxene
Valium
Xanax
Celexa
Lexapro
Luvox
Luvox CR
Paxil
Prozac
Zoloft

Number of Physicians Receiving Detailing Payments
2014
2015
2016
2017
2018
2019
1
1
3
2
2
5
2
1
Drugs selected form the ADAA’s medication guidelines.

19
Figure 2

Figure 3

20
Figure 4

Figure 5

21
Figure 6

Figure 7

22
Figure 8

Figure 9

23
Figure 10

Figure 11

24
Figure 12

